Cosmetic compositions for skin improvement and pharmaceutical compositions for the prevention or treatment of skin damage, containing honokiol and polyols.

Abstract

The present invention relates to a cosmetic composition for skin improvement and a pharmaceutical composition for the prevention or treatment of skin damage, comprising honokiol and a polyol. When honokiol is dissolved in a polyol, the effects of wrinkle improvement, elasticity improvement, moisturizing improvement, barrier improvement, inflammation suppression, and antioxidant activity are synergistically enhanced, making it effective for the production of cosmetic compositions for skin improvement or pharmaceutical compositions for the prevention or treatment of skin damage.

Description

Technical Field

[0001] This patent application claims priority to Korean Patent Application No. 10-2023-0085480, filed with the Korean Intellectual Property Office on July 3, 2023, and the disclosure of the said patent application is incorporated herein by reference.

[0002] The present invention relates to a cosmetic composition for improving skin containing honokiol and polyol, and a pharmaceutical composition for preventing or treating skin damage.

Background Art

[0003] Aging is a continuous functional, structural, and biochemical process that occurs from birth to death in a person, and occurs in cells and entire body tissues that make up the human body, causing a decrease in metabolic rate, an increase in diseases, a decrease in adaptability, etc., and ultimately leading to the death of cells and the entire body.

[0004] Among these, skin aging is studied mainly in two categories. One is "intrinsic aging", which is an aging phenomenon associated with aging over time, and the other is "extrinsic aging", which refers to an aging phenomenon caused by external environments, that is, ultraviolet rays, pollution, etc.

[0005] Regarding skin aging, various theories have been presented so far. Among them, the theory that is most scientifically close to skin aging is the theory of skin aging due to oxidation.

[0006] Human skin is composed of the epidermis (including the stratum corneum), the dermis, and connective tissue. The stratum corneum, in particular, is a layer of dead cells formed by the differentiation process of keratinocytes, which are basal cells of the epidermis, and plays a role in protecting the body from the effects of the external environment. The dermis, located inside the skin, is composed of collagen and elastin, which give the skin elasticity and protect it from sagging. The antioxidant theory posits that collagen and elastin are damaged by free radicals generated by external factors such as ultraviolet rays, resulting in a decrease in skin elasticity and the formation of wrinkles.

[0007] Until now, natural antioxidants such as vitamin E, vitamin C, carotenoids, glutathione, and plant extracts have been used to prevent skin aging, especially wrinkles. However, these substances have had problems, such as being ineffective or causing serious side effects on the skin, including skin irritation, redness, and inflammation.

[0008] In recent years, with the rise in popularity of retinol products, there has been an increasing consumer demand for a combination of powerful wrinkle-reducing effects and low irritation, similar to retinol. However, due to limitations in improving side effects such as phototoxicity, the need for natural materials as retinol alternatives that are less irritating and more effective has emerged. [Overview of the Initiative] [Problems that the invention aims to solve]

[0009] The inventors have confirmed that honokiol and polyols exhibit excellent skin elasticity enhancement, moisturizing properties, barrier improvement, inflammation reduction, and antioxidant activity.

[0010] Therefore, the object of the present invention is to provide a cosmetic composition for skin improvement containing honokiol and polyol.

[0011] Another object of the present invention is to provide a pharmaceutical composition comprising honokiol and polyol for the prevention or treatment of skin damage.

[0012] Further objections of the present invention relate to the skin-improving applications of honokiol and polyol, and to the prevention or treatment of photoaging of the skin caused by exposure to ultraviolet light. [Means for solving the problem]

[0013] The present invention relates to a cosmetic composition for improving skin, and a pharmaceutical composition for preventing or treating skin damage, comprising honokiol, a component derived from the bark of the magnolia tree, and a polyol. According to the present invention, when honokiol is dissolved in a polyol, it synergistically exhibits skin elasticity, moisturizing, barrier improvement, anti-inflammatory, and antioxidant activity.

[0014] The inventors confirmed the activity of honokiol and polyol on skin cells and found that they exhibit more effective elasticity, moisturizing, barrier improvement, inflammation suppression, and antioxidant effects compared to retinol, a known component.

[0015] The present invention will be described in more detail below.

[0016] One aspect of the present invention is a cosmetic composition for skin improvement comprising honocchiol and polyol.

[0017] In the present invention, the honokiol and polyol may be included in a weight ratio of 1:10 to 1:200, preferably 1:10 to 1:150, 1:10 to 1:100, 1:10 to 1:50, 1:10 to 1:20, 1:12 to 1:200, 1:12 to 1:150, 1:12 to 1:100, 1:12 to 1:50, and 1:12 to 1:2 It may be included in weight ratios of 0, 1:15-1:200, 1:15-1:150, 1:15-1:100, 1:15-1:50, 1:15-1:20, 1:18-1:200, 1:18-1:150, 1:18-1:100, or 1:18-1:50, for example, it may be included in weight ratios of 1:18-1:20, but is not limited thereto.

[0018] In the present invention, the honokiol may be present in an amount of 0.0001 to 50% by weight of the total weight of the cosmetic composition, preferably 0.0001 to 20% by weight, 0.0001 to 10% by weight, 0.0001 to 5% by weight, 0.0001 to 2% by weight, 0.0001 to 1% by weight, 0.0001 to 0.5% by weight, or 0.0001 to 0% by weight. 2% by weight, 0.0001~0.1% by weight, 0.001~50% by weight, 0.001~20% by weight, 0.001~10% by weight, 0.001~5% by weight, 0.001~ 2% by weight, 0.001~1% by weight, 0.001~0.5% by weight, 0.001~0.2% by weight, 0.001~0.1% by weight, 0.01~50% by weight, 0.01~20 Weight%, 0.01~10wt%, 0.01~5wt%, 0.01~2wt%, 0.01~1wt%, 0.01~0.5wt%, 0.01~0.2wt%, 0.0 1~0.1wt%, 0.1~50wt%, 0.1~20wt%, 0.1~10wt%, 0.1~5wt%, 0.1~2wt%, 0.1~1wt%, 0.1~0.5 It may contain, but is not limited to, weight%, 0.1-0.2 weight%, 1-50 weight%, 1-20 weight%, 1-10 weight%, 1-5 weight%, 1-2 weight%, 2-50 weight%, 2-20 weight%, 2-10 weight%, 2-5 weight%, 5-50 weight%, 5-20 weight%, 5-10 weight%, 10-50 weight%, or 10-20 weight%.

[0019] In the present invention, the polyol may be one or more selected from the group consisting of butylene glycol (BG) and propylene glycol (PG), and is preferably butylene glycol, but is not limited thereto.

[0020] In the present invention, the skin improvement may be an improvement in skin photoaging caused by exposure to ultraviolet light.

[0021] The ultraviolet light may be, for example, UVA (ultraviolet-A) or UVB (ultraviolet-B). However, it is not limited to these examples and includes any wavelength range of light that can induce photoaging of the skin.

[0022] In the present invention, the skin improvement may be one or more selected from the group consisting of wrinkle improvement, elasticity improvement, moisture improvement, barrier improvement, inflammation suppression, and antioxidant effects.

[0023] The cosmetic composition of the present invention may be in any dosage form commonly manufactured in the industry, and can be applied to general cosmetic compositions such as emulsions, lotions, essences, and creams, as well as various functional cosmetic compositions such as anti-aging cosmetics and whitening cosmetics.

[0024] Furthermore, the cosmetic composition may be manufactured in various dosage forms, and the dosage forms are not particularly limited. For example, it can be manufactured in forms such as cream, lotion, emulsion, essence, and more specifically, softening lotion, nourishing lotion, essence, nourishing emulsion, nourishing cream, eye cream, massage cream, cleansing cream, cleansing foam, cleansing water, powder, pack, hair cosmetics, body emulsion, body cream, body oil, body essence, body cleanser, etc.

[0025] As a preferred embodiment, the cosmetic composition of the present invention may be in the form of a cream, emulsion, or essence. The carrier or additive used at this time can be selectively used according to the form of the cosmetic.

[0026] Therefore, in addition to the above components, the cosmetic composition used in the present invention may further contain components generally used in cosmetics such as creams, emulsions, essences, etc., for example, oil and fat components, moisturizing agents, emollient agents, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, bactericides, antioxidants, plant extracts, pH adjusters, alcohols, dyes, fragrances, blood circulation promoters, cooling agents, antiperspirants, preservatives, and solvents, and fragrances can be further added according to preference.

[0027] When the dosage form of the present invention is a paste, cream, or gel, animal fibers, plant fibers, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicon, bentonite, silica, talc, or zinc oxide may be used as the carrier component. When the dosage form of the present invention is a powder or spray, lactose, talc, silica, aluminum oxide, calcium silicate, or polyamide powder may be used as the carrier component, and in particular, when it is a spray, it may further contain a propellant such as chlorofluorohydrocarbon, propane / butane, or dimethyl ether.

[0028] When the dosage form of the present invention is a solution or an emulsion, a solvent, a solubilizer or an emulsifier is used as the carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol fatty acid ester, polyethylene glycol, or fatty acid ester of sorbitan. When the dosage form of the present invention is a suspension, as the carrier component, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tragacanth may be used.

[0029] Another aspect of the present invention is a pharmaceutical composition for preventing or treating skin damage, which contains honokiol and a polyol.

[0030] In the present invention, the honokiol and the polyol may be contained in a weight ratio of 1:10 to 1:200, preferably 1:10 to 1:150, 1:10 to 1:100, 1:10 to 1:50, 1:10 to 1:20, 1:12 to 1:200, 1:12 to 1:150, 1:12 to 1:100, 1:12 to 1:50, 1:12 to 1:20, 1:15 to 1:200, 1:15 to 1:150, 1:15 to 1:100, 1:15 to 1:50, 1:15 to 1:20, 1:18 to 1:200, 1:18 to 1:150, 1:18 to 1:100, or 1:18 to 1:50, for example, may be contained in a weight ratio of 1:18 to 1:20, but is not limited thereto.

[0031] In the present invention, the honokiol may be present in an amount of 0.0001 to 50% by weight of the total weight of the cosmetic composition, preferably 0.0001 to 20% by weight, 0.0001 to 10% by weight, 0.0001 to 5% by weight, 0.0001 to 2% by weight, 0.0001 to 1% by weight, 0.0001 to 0.5% by weight, or 0.0001 to 0% by weight. 2% by weight, 0.0001~0.1% by weight, 0.001~50% by weight, 0.001~20% by weight, 0.001~10% by weight, 0.001~5% by weight, 0.001~ 2% by weight, 0.001~1% by weight, 0.001~0.5% by weight, 0.001~0.2% by weight, 0.001~0.1% by weight, 0.01~50% by weight, 0.01~20 Weight%, 0.01~10wt%, 0.01~5wt%, 0.01~2wt%, 0.01~1wt%, 0.01~0.5wt%, 0.01~0.2wt%, 0.0 1~0.1wt%, 0.1~50wt%, 0.1~20wt%, 0.1~10wt%, 0.1~5wt%, 0.1~2wt%, 0.1~1wt%, 0.1~0.5 It may contain, but is not limited to, weight%, 0.1-0.2 weight%, 1-50 weight%, 1-20 weight%, 1-10 weight%, 1-5 weight%, 1-2 weight%, 2-50 weight%, 2-20 weight%, 2-10 weight%, 2-5 weight%, 5-50 weight%, 5-20 weight%, 5-10 weight%, 10-50 weight%, or 10-20 weight%.

[0032] In the present invention, the polyol may be one or more selected from the group consisting of butylene glycol and propylene glycol, and is preferably butylene glycol, but is not limited thereto.

[0033] In the present invention, the skin damage may be photoaging of the skin caused by exposure to ultraviolet light.

[0034] The aforementioned ultraviolet light may be, for example, UVA or UVB. However, it is not limited to these examples and includes any wavelength range of light that can induce photoaging of the skin.

[0035] In the present invention, the skin damage caused by photoaging may be one or more selected from the group consisting of skin wrinkles, decreased skin elasticity, dry skin, impaired skin barrier function, and skin inflammation.

[0036] The pharmaceutical composition of the present invention may be used as a pharmaceutical composition comprising a pharmaceutically effective amount of honokiol and / or a pharmaceutically acceptable carrier.

[0037] In this specification, the term "pharmaceutical effective dose" means an amount sufficient to achieve the efficacy or activity of honokiol as described above.

[0038] The pharmaceutically acceptable carriers included in the pharmaceutical composition of the present invention are those commonly used in formulation and include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition to the above components, the pharmaceutical composition of the present invention may further include lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, and the like.

[0039] The pharmaceutical composition according to the present invention may be administered to mammals, including humans, via various routes. The administration method may be any commonly used method, for example, by oral, cutaneous, intravenous, intramuscular, or subcutaneous routes, and preferably by oral administration.

[0040] The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as the formulation method, administration method, patient's age, weight, sex, medical condition, diet, administration time, route of administration, excretion rate, and response sensitivity, and a skilled, ordinary physician can easily determine and prescribe a dosage effective for the desired treatment or prevention.

[0041] The pharmaceutical compositions of the present invention may be manufactured in unit dose form by formulation using pharmaceutically acceptable carriers and / or excipients by a method readily available to a person with ordinary skill in the art to which the invention pertains, or by being encapsulated in multi-dose containers. The dosage form may be in the form of a solution, suspension, or emulsion in an oil or aqueous medium, or in the form of an extract, powder, granules, tablet, capsule, or gel (e.g., hydrogel), and may further contain a dispersant or stabilizer. [Effects of the Invention]

[0042] The present invention relates to a cosmetic composition for skin improvement and a pharmaceutical composition for the prevention or treatment of skin damage, comprising honokiol and a polyol. When honokiol is dissolved in a polyol, the effects of wrinkle improvement, elasticity improvement, moisturizing improvement, barrier improvement, inflammation suppression, and antioxidant activity are synergistically enhanced, making it possible to effectively utilize this in the production of cosmetic compositions for skin improvement or pharmaceutical compositions for the prevention or treatment of skin damage. [Brief explanation of the drawing]

[0043] [Figure 1] Figure 1A is a graph showing the cytotoxicity of honokiol according to one embodiment of the present invention against stratum corneum cells of the skin. Figure 1B is a graph showing the cytotoxicity of honokiol according to one embodiment of the present invention against dermal cells of the skin.

[0044]

[0045] [Figure 2] Figure 2A is a graph showing the expression level of the collagen production-promoting gene COL1A by honokiol according to one embodiment of the present invention. Figure 2B is a graph showing the expression level of the collagen-degrading enzyme-inhibiting gene MMP-1 by honokiol according to one embodiment of the present invention.

[0046]

[0047] [Figure 3] Figure 3A is a graph showing the expression level of ELN1, a gene related to the promotion of elastin production by honokiol according to one embodiment of the present invention. Figure 3B is a graph showing the expression level of FBN, a gene related to the promotion of fibronectin production by honokiol according to one embodiment of the present invention.

[0048]

[0049] [Figure 4A] This graph shows the expression level of the water transport-related gene AQP3 present in the dermis of honokiol according to one embodiment of the present invention.

[0050] [Figure 4B] This graph shows the expression level of the hyaluronic acid synthase-related gene HAS3 in honokiol according to one embodiment of the present invention.

[0051] [Figure 5A] This graph shows the expression level of the moisturizing component-related gene FLG present in keratinocytes that form the skin barrier, according to one embodiment of the present invention.

[0052] [Figure 5B] This graph shows the expression level of CLDN1, a gene related to the skin barrier binding of honokiol according to one embodiment of the present invention.

[0053] [Figure 6] This graph shows the expression level of the inflammation-related gene TSLP expressed in skin keratinocytes of honokiol according to one embodiment of the present invention.

[0054] [Figure 7] This graph shows the antioxidant activity of honokiol according to one embodiment of the present invention.

[0055] [Figure 8]Figure 8A is a graph showing the expression level of the collagen production-promoting gene COL1A by solvent selection of honokiol according to one embodiment of the present invention. Figure 8B is a graph showing the expression level of the collagen-degrading enzyme-inhibiting gene MMP-1 by solvent selection of honokiol according to one embodiment of the present invention.

[0056]

[0057] [Figure 9] Figure 9A is a graph showing the expression level of the elastin production-promoting gene ELN1 by solvent selection of honokiol according to one embodiment of the present invention. Figure 9B is a graph showing the expression level of FLG, an epidermal cell production-promoting factor, by solvent selection of honokiol according to one embodiment of the present invention.

[0058] [Modes for carrying out the invention]

[0059] The present invention relates to a cosmetic composition for skin improvement comprising honokiol and a polyol. [Examples]

[0060] The present invention will be described in more detail below using the following examples. However, these examples are merely illustrative of the present invention, and the scope of the present invention is not limited by these examples.

[0061] Throughout this specification, unless otherwise specified, the percentages "%" used to indicate the concentration of a particular substance refer to (weight / weight)% for solid / solid, (weight / volume)% for solid / liquid, and (volume / volume)% for liquid / liquid.

[0062]

[0063] Example 1: Cytotoxicity Evaluation

[0064] The toxicity of honokiol on epidermal and dermal cells was evaluated.

[0065] Specifically, HaCaT cells (keratinocytes) and Hs68 cells (fibroblasts) were cultured in 96-well plates at a concentration of 2 × 10⁴ cells / well. They were then cultured for 24 hours in a medium containing Fetal Bovine Serum (FBS) and an antibiotic (Antibiotic antimycotic) at 37°C and 5% CO₂. The following day, the cells were further cultured in a medium containing only the antibiotic, treated with honokiol at concentrations of 0.1 ppm, 0.5 ppm, 1 ppm, and 5 ppm, respectively. After 24 hours, the medium was replaced with one containing MTT tetrazolium (Sigma-aldrich, St. Louis, USA), and the cells were incubated at 37°C for 4 hours to evaluate cellular reactivity and determine the toxic concentration of honokiol on skin cells.

[0066] As can be seen from Figures 1A and 1B, honokiol did not induce cytotoxicity in both stratum corneum and dermal cells at concentrations of 5 ppm or less.

[0067]

[0068] Example 2: Confirmation of the effect of honokiol

[0069] 2-1. Confirmation of collagen production

[0070] We investigated whether honokiol increases the amount of skin collagen.

[0071] Specifically, Hs68 cells, which are dermal cells, were irradiated with UVB (ultraviolet B) at an intensity of 25 mJ / cm2, and then treated with retinoic acid (RA), epigallocatechin gallate (EGCG), retinol, and honokiol at concentrations of 1 ppm each for 24 hours.

[0072] Subsequently, qRT-PCR analysis was used to measure the mRNA expression levels of COL1A1, a collagen synthesis-related factor, and the collagen-degrading enzyme factor MMP-1. These levels were then converted to a baseline of actin expression levels, and their relative values ​​were calculated and compared to those of the UVB-unirradiated group.

[0073] As can be seen in Figure 2A, the honokiol-treated group showed a higher collagen production compared to the UVB-only irradiation group, and exhibited the highest collagen production among all UVB irradiation groups.

[0074] As can be seen in Figure 2B, the honokiol-treated group showed lower collagen-degrading enzyme production compared to the UVB-only irradiation group.

[0075] As a result, it was confirmed that honokiol has the effect of increasing the collagen content in the skin by promoting collagen production and suppressing collagen breakdown.

[0076]

[0077] 2-2. Confirmation of the effect of increasing elasticity

[0078] We investigated whether honokiol increases skin elasticity.

[0079] Specifically, Hs68 cells, which are dermal cells, were irradiated with UVB (ultraviolet-B) at an intensity of 25 mJ / cm2, and then treated with RA, EGCG, retinol, and honokiol at 1 ppm each for 24 hours.

[0080] Subsequently, qRT-PCR analysis was used to measure the mRNA expression levels of ELN1, an elastin production-promoting factor, and FBN, a fibronectin production-promoting factor. These levels were then converted to a baseline of actin expression levels from the non-UVB irradiated group and compared.

[0081] As can be seen from Figures 3A and 3B, the honokiol-treated group showed the highest expression level among the UV-irradiated groups, and also showed a higher expression level compared to the non-UV-irradiated group.

[0082] As a result, it was confirmed that honokiol promotes the production of elastin and fibronectin, which are skin components responsible for elasticity, thereby increasing skin elasticity.

[0083]

[0084] 2-3. Confirmation of moisturizing improvement effect

[0085] We investigated whether honokiol improves skin hydration.

[0086] Specifically, HaCaT cells, which are keratinocytes of the skin stratum corneum, were treated with retinol and honokiol at concentrations of 0.1 ppm and 1 ppm, respectively, for 24 hours.

[0087] Subsequently, qRT-PCR analysis was used to measure the mRNA expression levels of AQP3, a water transport-related factor present in the dermis, and HAS3, a hyaluronic acid synthase-related factor. These levels were then converted to a baseline for comparison with β-actin expression levels.

[0088] As can be seen from Figures 4A and 4B, the honokiol-treated group not only showed generally higher expression levels compared to the retinol-treated group, but also significantly increased the expression levels of related genes, especially at 1 ppm treatment.

[0089] As a result, it was confirmed that honokiol improves skin hydration by activating moisture channels and promoting hyaluronic acid synthesis.

[0090]

[0091] 2-4. Confirmation of barrier improvement effect

[0092] We investigated whether honokiol improves the skin barrier.

[0093] Specifically, HaCaT cells, which are keratinocytes of the skin stratum corneum, were treated with retinol and honokiol at concentrations of 0.1 ppm and 1 ppm, respectively, for 24 hours.

[0094] Subsequently, qRT-PCR analysis was used to measure the mRNA expression levels of filaggrin (FLG), a moisturizing component-related factor present in keratinocytes that constitute the skin barrier, and the CLDN1 gene, a skin barrier binding-related factor. These levels were then converted to a baseline for comparison with β-actin expression levels.

[0095] As can be seen in Figure 5A, the honokiol-treated group not only showed generally higher expression levels compared to the retinol-treated group, but also significantly increased the expression level of the FLG gene, especially at 1 ppm treatment.

[0096] As can be seen in Figure 5B, the honokiol-treated group showed a significant increase in CLDN1 gene expression compared to the control group, particularly at 1 ppm treatment.

[0097] As a result, it was confirmed that honokiol improves skin hydration by promoting the differentiation of the skin barrier and strengthening the bonds between skin barrier cells.

[0098]

[0099] 2-5. Confirmation of the effect of reducing epidermal inflammation

[0100] We investigated whether honokiol alleviates inflammation of the skin's epidermis.

[0101] Specifically, HaCaT cells, which are keratinocytes of the skin stratum corneum, were treated (+) with the inflammatory response-inducing substances Poly I:C 10 μg / ml and IL-4 protein 10 μg / ml to induce an inflammatory response. Simultaneously, experimental groups were prepared in which the cells were treated for 4 hours each with the control anti-inflammatory substances dexamethasone (DEXA) 1 μM (Dexa), retinol, and honokiol, at concentrations of 0.1 ppm and 1 ppm, respectively. An untreated group (-) was prepared as a negative control group.

[0102] Subsequently, qRT-PCR analysis was used to measure the expression level of the TSLP gene, an inflammation-related factor expressed in skin keratinocytes, and compared by converting it to a baseline of actin expression levels.

[0103] As can be seen in Figure 6, in cells where an inflammatory response had been induced, the honokiol-treated group showed a significant decrease in TSLP gene expression at 1 ppm, confirming that it exerts an effect of alleviating epidermal inflammation.

[0104]

[0105] 2-6. Confirmation of antioxidant effects

[0106] The DPPH test was used to confirm whether honokiol exhibits antioxidant activity.

[0107] Specifically, DPPH solution was treated with 10 ppm and 100 ppm of ascorbic acid (AA), retinol, and honokiol, respectively, at room temperature for 30 minutes. Absorbance was measured at 517 nm, and antioxidant activity was indicated by the ratio of the decrease in absorbance compared to the control group. In this study, ascorbic acid, an antioxidant, was used as the control group to determine the ratio of the decrease in absorbance.

[0108] As can be seen in Figure 7, the honokiol-treated group was found to exhibit significantly higher antioxidant activity compared to the retinol-treated group.

[0109]

[0110] Example 3: Stabilization method for high-concentration honokiol

[0111] 3-1. Selection of solvents

[0112] Honokiol is a poorly soluble component with low solubility in water, requiring dissolution in an organic solvent. Therefore, to stabilize a cosmetic composition containing 5% by weight of honokiol, we investigated the use of three solvents: water, butylene glycol (BG), and medium-chain triglyceride (MCT) oil.

[0113] [Table 1] [Table 1]

[0114] As can be seen from Table 1 above, when honokiol was dissolved at 5% by weight, its solubility in water was low, but it was confirmed to dissolve well in BG and MCT.

[0115]

[0116] 3-2. Stability and titer testing using selected solvents

[0117] Honokiol was dissolved in BG and MCT at a concentration of 5% by weight, and the presence or absence of precipitate formation was observed under conditions of 4°C, 25°C, 45°C, 50°C, and sunlight. High-performance liquid chromatography (HPLC) was then performed for titer analysis.

[0118] [Table 2] [Table 2]

[0119] As can be seen from Table 2 above, honokiol maintained its potency well even under harsh conditions of low temperature, high temperature, and cycling, indicating excellent stability of the substance itself. Next, after preparing the same composition, the presence or absence of precipitate formation was checked for three months under conditions of 4°C, 25°C, 45°C, 50°C, and sunlight.

[0120] [Table 3] [Table 3]

[0121] As can be seen from Table 3 above, when BG and MCT were used as solvents, overall stability was observed under all conditions. However, in the case of MCT, precipitation occurred under high temperature conditions starting after 1 month (1M), showing a different pattern from BG, and signs of precipitation were observed at 25°C and under sunlight conditions. This was judged to be due to the high stability of the honokiol component itself, but its low solubility in MCT. No significant differences in properties were found between the results after 3 months and 1 month.

[0122] In conclusion, it was confirmed that poorly soluble honokhiol exhibits higher solubility in water-soluble polyols compared to oil-soluble oils.

[0123]

[0124] Example 4: Confirmation of the effect of the combination of honokiol and solvent.

[0125] 4-1. Confirmation of collagen production

[0126] The amount of collagen produced was compared using the same method as in Example 2-1 above, but the treated samples were changed to honokiol solutions dissolved in RA (retinoic acid), retinol, DMSO (dimethyl sulfoxide), honokiol solutions dissolved in BG, and honokiol solutions dissolved in PG (propylene glycol).

[0127] Unlike Example 2-1 above, where a 5% (w / w) solution was prepared as a sample to confirm stability in a high-concentration dissolved state, the honokiol solution for treating the cells was prepared at a concentration of 1 mg / ml, so that the honokiol component alone that treated the cells was 1 ppm.

[0128] As can be seen in Figure 8A, the group treated with honocchiol solution dissolved in BG showed a higher collagen production compared to the UVB-only irradiation group, and exhibited the highest collagen production among all UVB irradiation groups.

[0129] As can be seen in Figure 8B, all honokiol solution-treated groups showed lower collagen-degrading enzyme production compared to the UVB-only irradiation group.

[0130]

[0131] 4-2. Confirmation of the effect of increasing elasticity

[0132] The degree of increase in skin elasticity was compared using the same method as in Example 2-2 described above, but the mRNA expression levels of ELN1, an elastin production-related factor, and FLG, an epidermal cell production-related factor, were measured and compared using the actin expression level from the UVB non-irradiated group as a baseline.

[0133] The treated samples were prepared in the same manner as in Example 4-1 above, as honokiol solutions dissolved in RA, retinol, and DMSO (Dimethyl Sulfoxide), honokiol solutions dissolved in BG, and honokiol solutions dissolved in PG (Propylene Glycol), so that the concentration of honokiol alone that was treated on the cells was 1 ppm.

[0134] As can be seen from Figures 9A and 9B, the group treated with honokiol solution dissolved in BG showed the highest expression level among the UV-irradiated groups, and also showed a higher expression level than the non-UV-irradiated group, resulting in the highest expression level among all UVB-irradiated groups.

[0135] As a result, it was confirmed that honokiol promotes the production of elastin and fibronectin, which are skin components responsible for elasticity, thereby increasing skin elasticity. [Industrial applicability]

[0136] The present invention relates to cosmetic compositions for skin improvement and pharmaceutical compositions for the prevention or treatment of skin damage, comprising honokiol and polyol.

Claims

1. A cosmetic composition for skin improvement containing honokiol and polyol.

2. The cosmetic composition according to claim 1, wherein the honokiol is contained in an amount of 0.0001 to 50% by weight of the total weight of the cosmetic composition.

3. The cosmetic composition according to claim 1, wherein the polyol is one or more selected from the group consisting of butylene glycol (BG) and propylene glycol (PG).

4. The cosmetic composition according to claim 1, wherein the skin improvement is an improvement in skin photoaging caused by exposure to ultraviolet light.

5. The cosmetic composition according to claim 1, wherein the skin improvement is one or more selected from the group consisting of wrinkle improvement, elasticity improvement, moisture improvement, barrier improvement, inflammation suppression, and antioxidant effects.

6. A pharmaceutical composition comprising honokiol and a polyol for the prevention or treatment of skin damage.

7. The pharmaceutical composition according to claim 6, wherein the honokiol is contained in an amount of 0.0001 to 50% by weight of the total weight of the cosmetic composition.

8. The pharmaceutical composition according to claim 6, wherein the polyol is one or more selected from the group consisting of butylene glycol (BG) and propylene glycol (PG).

9. The pharmaceutical composition according to claim 6, wherein the skin damage is photoaging of the skin caused by exposure to ultraviolet light.

10. The pharmaceutical composition according to claim 6, wherein the skin injury is one or more selected from the group consisting of skin wrinkles, decreased skin elasticity, xerosis, impaired skin barrier function, and skin inflammation.

Images